Patents by Inventor Sergei Svarovsky

Sergei Svarovsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160361332
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Application
    Filed: June 14, 2016
    Publication date: December 15, 2016
    Inventors: John L. Magnani, John T. Patton, Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • Publication number: 20140178303
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Application
    Filed: December 13, 2013
    Publication date: June 26, 2014
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • Patent number: 8633303
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: January 21, 2014
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • Patent number: 8124329
    Abstract: A method for hypothermic preservation of biological tissue for later recovery to a viable state includes flushing the biological tissue with a gas mixture of sulfur hexafluoride or xenon and oxygen. The sulfur hexafluoride or xenon is in a concentration in the mixture between about 75 mole percent to 95 mole percent. The method includes pressurizing the biological tissue, preferably isothermically, with the mixture to a pressure that will form clathrates inside the biological tissue at a desired storage temperature in a range of about +1° C. to about +5° C. The method includes a step of cooling the biological tissue, preferably isobarically, to the desired storage temperature. Optional steps for further cooling to no colder than about ?20° C. and for depressurization are provided as well as steps for recovering the hypothermically preserved biological tissue to a viable state, preferably using a recovery gas mixture.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: February 28, 2012
    Inventors: Sergey V. Sheleg, Hugh LeRoy Hixon, Jr., Sergei A. Svarovsky, Bruce Cohen
  • Publication number: 20120004190
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Application
    Filed: June 21, 2011
    Publication date: January 5, 2012
    Applicant: GlycoMimetics, Inc.
    Inventors: John L. MAGNANI, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • Patent number: 7989601
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: August 2, 2011
    Assignee: GlycoMimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • Publication number: 20110136727
    Abstract: Isolated glycan binding peptide complex comprise two or more glycan binding peptides operatively coupled to each other. These are bacterial binding peptide conjugates (e.g., glycan binding peptides) to a multivalent polymer (e.g., a multivalent PEG molecule) or to the surface of particles that create multimeric constructs that inhibit growth and aggregation of microbes. Included is a method of evaluating a substance for the presence of a microbe comprising contacting the substance with a peptide microarray or a peptide complex comprising a plurality glycan binding peptide operatively coupled to a substrate or multivalent linker, wherein the glycan binding peptide is coupled to an array by a linker that is at least 0.5 micrometers in length.
    Type: Application
    Filed: November 20, 2010
    Publication date: June 9, 2011
    Inventor: SERGEI SVAROVSKY
  • Patent number: 7790473
    Abstract: Novel biofunctionalized quantum dots include a mercaptoalkanoic acid linked to the surface of a nanocrystalline core and a bio-functional group linked to the surface. Biofunctionalized quantum dots are made by a novel synthesis method. Biofunctionalized quantum dots can be used in imaging or therapy applications.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: September 7, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Joseph J. Barchi, Jr., Sergei A. Svarovsky
  • Publication number: 20100204170
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Application
    Filed: April 20, 2010
    Publication date: August 12, 2010
    Applicant: GlycoMimetics, Inc.
    Inventors: John L. MAGNANI, John T. PATTON, JR., Arun K. SARKAR, Sergei A. SVAROVSKY, Beat ERNST
  • Patent number: 7728117
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: June 1, 2010
    Assignee: GlycoMimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • Publication number: 20090286220
    Abstract: A method for hypothermic preservation of biological tissue for later recovery to a viable state includes flushing the biological tissue with a gas mixture of sulfur hexafluoride or xenon and oxygen. The sulfur hexafluoride or xenon is in a concentration in the mixture between about 75 mole percent to 95 mole percent. The method includes pressurizing the biological tissue, preferably isothermically, with the mixture to a pressure that will form clathrates inside the biological tissue at a desired storage temperature in a range of about +1° C. to about +5° C. The method includes a step of cooling the biological tissue, preferably isobarically, to the desired storage temperature. Optional steps for further cooling to no colder than about ?20° C. and for depressurization are provided as well as steps for recovering the hypothermically preserved biological tissue to a viable state, preferably using a recovery gas mixture.
    Type: Application
    Filed: May 7, 2009
    Publication date: November 19, 2009
    Applicant: IBPT CORPORATION
    Inventors: Sergey V. Sheleg, Hugh L. Hixon, JR., Bruce Cohen, Sergei A. Svarovsky
  • Publication number: 20080039816
    Abstract: Bio-functionalized quantum dots include a luminescence-enhancing mercaptoalkanoic acid and/or an ethylene glycol linked to the surface of a nanocrystalline core and a biofunctional group linked to the surface. The bio-functionalized quantum dots are made by an efficient synthesis method. The bio-functionalized quantum dots can be used in imaging or therapy applications.
    Type: Application
    Filed: March 22, 2005
    Publication date: February 14, 2008
    Applicant: The Government of the United States of America as represented by the Secretary, Department of
    Inventors: Sergei Svarovsky, Joseph Barchi
  • Publication number: 20070275007
    Abstract: Carbohydrate antigen-nanoparticle conjugates are disclosed. Methods of making carbohydrate antigen-nanoparticle conjugates are also disclosed. The carbohydrate antigen-nanoparticle conjugates can be used to inhibit metastasis of tumor cells in mammals.
    Type: Application
    Filed: October 27, 2004
    Publication date: November 29, 2007
    Applicants: The Government of the United States of America, represented by the Secretary of Health and Human S, The Research Foundation of State University of New York
    Inventors: Joseph Barchi, Kate Rittenhouse-Olson, Sergei Svarovsky
  • Publication number: 20070054870
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Application
    Filed: September 1, 2006
    Publication date: March 8, 2007
    Applicant: GlycoMimetics, Inc.
    Inventors: John Magnani, John Patton, Arun Sarkar, Sergei Svarovsky, Beat Ernst
  • Patent number: RE44778
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: February 25, 2014
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst